相关临床试验
182
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1924
进行中（未招募）
3
1.6%
已完成
105
57.7%
Enrolling By Invitation
1
0.6%
尚未招募
7
3.9%
招募中
20
11.0%
终止
4
2.2%
Unknown
42
23.1%
暂无批准数据
- A French randomized trial (LOMBACT) found adults who added a soft lumbar belt to usual care reported greater improvements in daily functioning than those receiving usual care alone. - About 6 in 10 belt users achieved at least a 30% reduction in daily limitations, compared with roughly 4 in 10 in the control group. - Around half of belt users took pain medication during follow-up, versus about two-thirds of the comparison group. - A separate Cochrane review found very low-quality evidence overall, leaving uncertainty about whether back braces provide meaningful long-term relief.
- The FDA has granted breakthrough device designation to the SonoClear System, an acoustic coupling fluid designed to improve ultrasound clarity during brain tumor resection surgery. - The system addresses critical imaging limitations by eliminating acoustic artifacts that standard irrigation fluids create, which typically obscure tumor remnants at the base of resection cavities. - Clinical data demonstrates the system's ability to provide clearer visualization of tumor margins, potentially enabling more complete tumor removal and improved surgical decision-making. - SonoClear AS becomes the first fully Norwegian-owned company to receive FDA breakthrough device designation and has secured funding for final product testing and 510(k) submission.
- Phase 2 clinical trial demonstrates IFB-088 (icerguastat) meets primary safety endpoint and shows significant reduction in disease progression for bulbar-onset ALS patients. - Treated patients in the per protocol population showed notably slower decline, losing 0.95 points monthly on ALSFRS-R compared to 1.42 points in the placebo group. - Biomarker data confirms IFB-088's mechanism of action through integrated stress response activation and oxidative stress reduction, supporting further development.
• Newronika has received FDA Investigational Device Exemption (IDE) approval to commence a pivotal trial evaluating their adaptive deep brain stimulation system for movement disorders, particularly Parkinson's disease. • The company's innovative AlphaDBS system utilizes real-time brain signal feedback to deliver personalized stimulation therapy, potentially offering improved outcomes over conventional DBS treatments. • The upcoming multinational pivotal trial will compare the adaptive system's performance against traditional DBS in advanced Parkinson's disease patients, marking a crucial step toward U.S. regulatory approval.
- New trial results from the Destiny-Breast06 study show Enhertu reduced the risk of HER2-low breast cancer progression by 38% compared to standard chemotherapy, with patients living without disease progression for 13.2 months versus 8.1 months. - The drug demonstrated superior efficacy with 60% of patients responding to treatment compared to 30% with chemotherapy, building on previous studies showing overall survival improvements of over six months. - Despite compelling clinical evidence, approximately 1,000 women annually in England and Wales are denied access to Enhertu due to NICE's cost-effectiveness concerns, while the drug remains available in Scotland and 13 other European countries. - Patient advocates and charities describe the access disparity as "utterly unacceptable," with ongoing negotiations between NICE, NHS England, and manufacturers Daiichi Sankyo and AstraZeneca to resolve pricing issues.
